Ranibizumab biosimilar - Formycon/Bioeq

Drug Profile

Ranibizumab biosimilar - Formycon/Bioeq

Alternative Names: FYB201

Latest Information Update: 09 Aug 2016

Price : $50

At a glance

  • Originator Formycon
  • Developer Bioeq; Formycon
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Wet age-related macular degeneration

Most Recent Events

  • 25 Jul 2016 9199913- No relevant info to update
  • 19 May 2016 Santo Holding/bioeq in-licenses ranibizumab from Formycon
  • 19 May 2016 Formycon initiates enrolment in a phase III trial for Wet age-related macular degeneration (NCT02611778)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top